| | |
Summary: 1
Silibinin mode of action(s) against HCV: A controversy yet to be resolved
Harel Dahari1,2
, Jeremie Guedj1
, Alan S. Perelson1
1
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545; 2
Department of Medicine,
University of Illinois at Chicago, Chicago, IL 60612
Dear Sir,
Ahmed-Belkacem et al.1
suggested that silymarin components (such as silibinin A and silibinin B or Legalon-SIL
(SIL), a commercially available intravenous (IV) preparation of silibinin) mainly inhibit HCV NS5B RNA-
dependent RNA polymerase (RdRp) activity. Here we note the HCV kinetics observed in patients treated with
SIL2-4
and the HCV-RdRp inhibitor RG7128 (5
and manuscript in preparation) have similarities and suggest
further studies to better understand SIL's MOAs in vivo.
To our best knowledge three clinical studies have reported the viral response during SIL therapy: one clinical
trial2
|
